北京美科美生物公司代理glycotech

Cancer Diagnostics
Human Selectins
Carbohydrate Polymers
Carbohydrate Antibodies
HSABSA Conjugates
Cell Adhesion Apparatus
Human Endothelial Cells
Carbohydrates / Reagents
Carbohydrate Adsorbents
Research Protocols

使命宣言
基于糖缀合物与其受体之间相互作用的生物学功能，发现和开发一类新的药物化合物。
GlycoTech 成立于 1991 年，今天仍然是专注于糖缀合物的生物功能和医学应用的主要公司之一。该公司已经建立了自己的研究计划并开发了大量的知识产权组合。通过其目录业务，GlycoTech 还建立了全球最大的稀有碳水化合物试剂和技术库之一。
在过去的六年中，GlycoTech 一直与诺华公司保持合作伙伴关系，以开发碳水化合物配体的小分子模拟物，作为在移植诱导的再灌注损伤期间淋巴细胞从血流中异常外渗的有效拮抗剂。
此外，最近与 Chiron Corporation 签订了许可协议，使用 GlycoTech 拥有的抗碳水化合物肿瘤标记物在全球范围内销售癌症诊断。
还与美国国立卫生研究院、宾夕法尼亚大学、罗彻斯特大学和芝加哥神经外科和神经研究所建立了研究协议。
GlycoTech 正在积极寻找其他制药合作伙伴，并提供专注于糖生物学领域的综合专业知识。 GlycoTech 的公司结构和战略使其合作伙伴能够快速获得这种独特的专业知识，并避免与内部有机增长相关的固定财务责任所遇到的义务。我们欢迎有机会与所有感兴趣的各方会面，探讨相互建设性的合作。
精细化学品和试剂业务
GlycoTech 的这一部门的目的是为所有科学家提供技术和试剂，以便将碳水化合物的研究扩展到其他研究领域，如细胞生物学、免疫学、神经生物学和分子生物学。目录的第一部分包含由知名科学家编写的一些有用的协议，涵盖糖生物学的广泛主题。以下部分包含各种独特的碳水化合物试剂，允许在不一定专门从事糖生物学的实验室中遵循许多这些协议。该目录还欢迎该领域的科学家参与，以积极支持他们的研究和发现。 GlycoTech 的长期目标是利用我们的技术和试剂研究基于糖缀合物与其受体相互作用的碳水化合物生物学功能的新发现。我们希望这个目录能够实现这些目标，并促进发现在生物医学界的应用。
Mission Statement
To discover and develop a new class of pharmaceutical compounds based on the biological functions of the interactions between glycoconjugates and their receptors.
GlycoTech was founded in 1991 and remains today as one of the premier companies focusing on the biological functions and medical applications of glycoconjugates.   The company has established its own research programs and has developed a large intellectual property portfolio.  Through its catalog business, GlycoTech has also established one of the largest libraries of rare carbohydrate reagents and technologies worldwide.
GlycoTech has maintained a corporate alliance with Novartis for the past six years to develop small molecule mimics of carbohydrate ligands as potent antagonists for the aberrant extravasation of lymphocytes from the bloodstream during transplantation-induced reperfusion injury.
In addition, licensing agreements were recently established with Chiron Corporation for worldwide sales in cancer diagnostics using anti-carbohydrate tumor markers owned by GlycoTech.
Research agreements have also been established with the National Institutes of Health, the University of Pennsylvania, the University of Rochester, and the Chicago Institute for Neurosurgery and Neuroresearch.
GlycoTech is actively seeking other pharmaceutical partners and offers a combined range of expertise focusing on the Glycobiology area. The corporate structure and strategy of GlycoTech allows its partners to quickly obtain this unique expertise and avoid the obligations encountered with the fixed financial responsibilities associated with internal organic growth.  We welcome the opportunity to meet with all interested parties to explore mutually constructive collaborations.
FINE CHEMICALS and REAGENTS BUSINESS
The purpose of this division of GlycoTech is to make techniques and reagents available to all scientists in order to broaden investigations of carbohydrates into other fields of research such as Cell Biology, Immunology, Neurobiology, and Molecular Biology. The first section of the catalog contains some useful protocols written by well known scientists covering a wide range of topics in Glycobiology. The following sections contain a variety of unique carbohydrate reagents that allow many of these protocols to be followed in laboratories not necessarily specializing in Glycobiology. This catalog also welcomes the participation of scientists within this field with the objective to actively support their research and discoveries. GlycoTech's long-term goal is to use our technology and reagents for research towards new discoveries of the biological functions of carbohydrates based on the interaction of glycoconjugates and their receptors. We hope that this catalog fulfills these goals and promotes the application of discoveries to the biomedical community.